The conversation centers on the evolving regulatory landscape of peptides and stem cells, particularly the challenges posed by pharmaceutical lobbying and the potential for state-level action to drive change. The guest, an expert in regenerative medicine, highlights the FDA's reclassification efforts regarding peptides and the dogma surrounding hormone therapies, including testosterone's link to prostate cancer, which stems from a study with flawed methodology. The discussion covers GLP-1 weight loss drugs, the influence of big pharma, and the need for affordable, accessible healthcare. The guest champions a cash-pay model focused on preventative care, citing the potential of gene sequencing and MUSE stem cells to revolutionize treatment. The conversation also touches on the potential of Texas to become a medical tourism destination by establishing a regulatory pathway for stem cell therapies.
Sign in to continue reading, translating and more.
Continue
